Personalized Medicine
Immunotherapies have significantly changed the treatment and disease outcome of patients with many types of solid cancers and hematologic neoplasias. At iiT, we use tumor biology and mathematical modeling to guide the optimal choice of immunotherapy for patients with lymphoma and leukemia — maximizing treatment success and minimizing side effects.
We provide the right treatment, individually tailored to each patient.
The Challenge
A New Era of Cancer Immunotherapy
Over the past decade, advances in immunotherapeutic strategies — particularly the development of immune checkpoint inhibitors, antibody–drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies — have revolutionized the therapeutic landscape of oncology. These modalities have demonstrated unprecedented efficacy across multiple malignancies, resulting in durable clinical responses and markedly improved survival outcomes in patient populations previously refractory to conventional treatments.
However, despite these breakthroughs, one key question remains:
Which therapy works best for which patient?
Lymphomas and leukemias can respond very differently to treatments like CAR T-cells or bispecific antibodies. Understanding the biological and molecular basis of this variation is essential to make therapy decisions truly personalized.
Our Vision & Approach
Turning Data into Personalized Therapy
iiT develops computational tools that predict the most effective immunotherapy for each individual patient.
By integrating tumor biology, immune profiling, and mathematical modeling, we aim to:
- Optimize therapy decisions in lymphoma and leukemia
- Reduce unnecessary side effects
- Improve clinical trial design
- Enable smarter use of healthcare resources
Research & Innovation
Scientific Innovation at the Interface of Biology and Mathematics
By fusing computational intelligence with biological understanding, we aim to transform immunotherapy and redefine cancer treatment.
Current Research Topics:
- Predictive models for therapy response in B-cell lymphomas and leukemias
- Integration of molecular and immunological biomarkers
- Simulation of treatment outcomes using patient-derived data
Collaborations:
We work closely with the Salzburg Cancer Research Institute (SCRI) — Laboratory of Immunological and Molecular Cancer Research — and maintain a strong partnership between laboratory science and in silico modeling at the iiT Computational Lab.
News
Stay informed
Here you can find information on our current research projects and ongoing developments. We will keep you informed of the latest progress.
Location
From Bench to Algorithm — Our Research Environment
Our laboratory work takes place at the Salzburg Cancer Research Institute, Laboratory of Immunological and Molecular Cancer Research.
Computational development and model simulations are conducted at the iiT Computational Lab, ensuring a seamless bridge between experimental and in silico research.
Team
Interdisciplinary Expertise Driving Innovation
Our team unites medical oncologists, tumor immunologists, and mathematicians — working hand in hand to translate biological complexity into clinical precision.
Univ.-Prof. Dr. Richard Greil
- Nationality: Austrian
- Field: Internal Medicine, Hematology & Oncology
- Positions:
- Head, Department of Internal Medicine III, University Hospital Salzburg (PMU) 1/2004 – 12/2024
- Founder & Director, Salzburg Cancer Research Institute (SCRI)
- Head, Austrian Group for Medical Tumor Therapy (AGMT)
- Research Focus:
- Translational cancer research
- Precision medicine
- Immunotherapy
- Clinical oncology and clinical trials
- Achievements:
- Extensive scientific publications
- leadership in national & international ocology networks
- City of Salzburg International Award for Science & Research (2020)
- 2021 Honorary Medal in Silver of the Republic of Austria for Special Merits for the Republic of Austria
- 2024 Honorary Medal by the Province of Salzburg
- Affiliations: American Society of Hematology (ASH), American Association of Cancer Research (AACR), American Society of Clinic al Oncology (ASCO), and ÖGHO
Cancer expert Univ.-Prof. Dr. Richard Greil ranks among the most highly cited physicians worldwide, underscoring his prominent role within the scientific community and his substantial contributions to medical research. His extensive body of work, published in leading peer-reviewed journals, has received international recognition and is frequently referenced by fellow researchers and clinicians. This not only attests to the quality and relevance of his work but also highlights the significant impact of his research on the field of oncology and beyond.
Particularly notable are his contributions to the study of leukemias, lymphomas, and solid tumors, as well as his pioneering efforts in the development of novel therapies and precision medicine. These achievements have been central to establishing him as one of the most cited cancer experts globally. Prof. Dr. Greil’s research has generated critical insights that have advanced clinical practice and facilitated the development of innovative treatment strategies.
The consistently high citation rate of his publications further reflects the importance of his work to the scientific community, demonstrating that his findings are widely respected and actively applied by colleagues around the world to drive forward oncological research and patient care.
Contact us
We are open to collaborations and partnerships that advance personalized immunotherapy.
Location: Salzburg Cancer Research Institute & iiT Computational Lab
Address:
iiT Research & Development GmbH
Strubergasse 18
A-5020 Salzburg
E-Mail: office@iit-research.at
Phone number: +43 662 23 04 92 400
